登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Biospace，1月5日，Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA》

  • 来源专题：COVID-19科研动态监测
  • 编译者： YUTING
  • 发布时间：2022-01-10

  • CHENGDU, China, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Inc., (Clover; Stock code: 2197.HK), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that the first participants have been dosed with Clover’s COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a homologous booster dose following primary vaccination of SCB-2019 (CpG 1018/Alum) in the ongoing global Phase 2/3 SPECTRA clinical trial. Clover reported final efficacy data for SCB-2019 (CpG 1018/Alum) in SPECTRA in September 2021 and the study is continuing to generate additional immunogenicity and safety data.

    This double-blind, randomized, controlled study will evaluate the immunogenicity and safety of two formulations of SCB-2019 (full dose: 30 µg with CpG 1018/Alum and half dose: 15 µg with CpG 1018/Alum) as a homologous booster dose administered approximately 6 months following 2-dose primary vaccination with SCB-2019 (CpG 1018/Alum) in approximately 4,000 adult participants.

    In addition, the evaluation of the immunogenicity and safety of SCB-2019 (CpG 1018/Alum) for primary vaccination in the adolescent (12-18 years) subgroup has been expanded to 1,200 adolescents. Initial data on both the homologous booster arm and adolescents are anticipated in the first half of 2022.

  • 原文来源：https://www.biospace.com/article/releases/clover-doses-first-participants-with-homologous-booster-dose-of-covid-19-vaccine-candidate-in-spectra/?keywords=COVID-19
109浏览量
原文链接
相关报告

  • 《Medicalxpress，1月4日，Early data for multivariant COVID-19 vaccine booster shows promise》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-01-10
    • The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response. U.S.-based biotechnology company Gritstone bio, Inc. in collaboration with The University of Manchester and Manchester University NHS Foundation Trust today (4 January 2022) reveal the initial phase one clinical data shows the vaccine has strong levels of neutralizing antibodies, similar to approved mRNA vaccines, but at up to a 10-fold lower dose in the first 10 individuals. Results also show the vaccine, which is being trialed with the anticipated involvement of 20 people aged 60 and over, who were in good health and previously received two doses of AstraZeneca's first-generation COVID-19 vaccine, was generally safe and well-tolerated. Part of Gritstone's CORAL program, the compound is a self-amplifying mRNA second generation SARS-CoV-2 vaccine—or samRNA for short—which delivers antigens from both spike and non-spike proteins. The samRNA vaccine also produced broad CD8+ T cell responses against targets from conserved SARS-CoV-2 viral proteins and boosted spike-specific T cells. Based on results, the trial is now being expanded to 120 people, potentially enabling more rapid advancement into a later stage trial.
    123浏览量
    原文链接

  • 《bioRxiv，6月20日，Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-22
    • Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 View ORCID ProfileSimon P Graham, View ORCID ProfileRebecca K McLean, View ORCID ProfileAlexandra J Spencer, View ORCID ProfileSandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, Jane C Edwards, Jack W P Hayes, Veronica Martini, Nazia Thakur, doi: https://doi.org/10.1101/2020.06.20.159715 Abstract Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
    51浏览量
    原文链接